This Is MS Multiple Sclerosis Community: Knowledge & Support

A team from The Scripps Research Institute has recently discovered that Gilenya's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent the first MS therapy with direct CNS activities.

The attached link provides more details.....

http://www.alphagalileo.org/ViewItem.as ... ureCode=en

Al

Sounds very good.

While this is interesting news, but imo. its "only" relevant from a scientific point of view as opposed to direct patients interest. After all, the published results from clinical trials (MRI lesion, annual relapse rate, EDSS progression etc.) are what they are. The mechanism of action - other than the modification of the immune response - underlying these outcomes is interesting (e.g. for the development of new drugs) but imo. not relevant for a patients therapy-decision whatsoever.

--Frank

_________________
Treatment: CCSVI both IJV ballooned 09/2010, No DMDs, Tysabri on hold after 24 Infusions, after LDN, ABX Wheldon Regime for 1 year.

This could be a HUGE fringe benefit of taking this. I haven't suffered badly from nerve death yet, but fewer relapses less severe relapses & nerve protection sound like a pretty good COMBO to me ;o)